BioSpace News Archive

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

Slowing of neuropathy progression for all 7 evaluable patients, evidenced by a +1.29 point mean change in NIS, was more favorable than expected progression of +9.2 points

Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, announced the initiation of a Phase 2 study of the company’s lead drug candidate, STP705, for Keloid scar prevention.

Transcenta Holding Limited announced the first patient has been successfully dosed in Phase I clinical study of TST001, a humanized monoclonal antibody targeting human Claudin18.2, in combination with CAPOX for the treatment of patients with first-line locally advanced unresectable or metastatic gastric cancer.

Data demonstrate LYN-005 quickly reaches therapeutic levels in patients, provides sustained risperidone drug levels for repeat one-week dosing intervals and reduces peak drug exposure